Dr. Safran is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
164 Summit Ave
# Fain
Providence, RI 02906Phone+1 401-793-2920Fax+1 401-444-2127
Education & Training
- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
- Boston University Medical CenterResidency, Internal Medicine, 1987 - 1990
- Boston University School of MedicineClass of 1987
Certifications & Licensure
- RI State Medical License 1993 - 2026
- MA State Medical License 1989 - 2025
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Start of enrollment: 1998 Jan 01
- Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas Start of enrollment: 1999 Mar 01
- A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema Start of enrollment: 2006 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsOvercoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).Matthew J Hadfield, Howard Safran, Marco A Purbhoo, Joseph E Grossman, Jennifer S Buell
Oncogene. 2024-03-01 - Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran
Clinical Cancer Research. 2024-02-01 - Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (B...Khaldoun Almhanna, Rimini Breakstone, Alexander Raufi, Roxanne Wood, Amy Webber
Translational Gastroenterology and Hepatology. 2024-01-01
Lectures
- Glycogen synthase kinase-3 beta (GSK-3β) blockade with 9-ing-41 in gastrointestinal cancers: The 1801 phase Ib/II study.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Adjuvant FOLFOX + nab-paclitaxel (FOLFOX-A)for pancreatic cancer, BrUOG 278: A Brown University oncology research group phase II study.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
- Working to Close the Cancer Screening Gap Caused by COVIDMay 17th, 2022
- Dana-Farber Cancer Institute and Lifespan Renew Strategic Alliance AgreementMarch 23rd, 2022
- Trastuzumab Combined with Trimodality Treatment for HER2-Overexpressing Esophageal Cancer Found to Be IneffectiveJanuary 22nd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: